STOCK TITAN
  1. Home
  2. News
  3. ALPN

Alpine Immune Sciences Inc - ALPN STOCK NEWS

Welcome to our dedicated news page for Alpine Immune Sciences (Ticker: ALPN), a resource for investors and traders seeking the latest updates and insights on Alpine Immune Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alpine Immune Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alpine Immune Sciences's position in the market.

News
Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie
Rhea-AI Summary
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) has announced the amendment of the 2020 option and license agreement with AbbVie for acazicolcept. Enrollment in the phase 2 study of acazicolcept in systemic lupus erythematosus will be stopped to allow for early assessment of data, with the final analysis expected by the end of 2024. AbbVie retains an exclusive option to obtain a worldwide license to acazicolcept with reduced milestone payments and royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none
-
News
Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Alpine Immune Sciences, Inc. (ALPN) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.39%
Tags
conferences
-
News
Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference
Rhea-AI Summary
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) to participate in Evercore ISI HealthconX Conference, November 28-30, 2023, including a fireside chat and investor meetings. Live webcast and replay available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.99%
Tags
conferences
News
Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
Rhea-AI Summary
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) presented new translational data for povetacicept (ALPN-303) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023. The data indicates that potent inhibition of both BAFF and APRIL may be required to achieve optimal efficacy in treating SLE. Povetacicept showed promising results in reducing disease parameters in a mouse model of lupus, outperforming conventional treatments. The company plans to initiate a phase 2 clinical study for SLE in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.6%
Tags
none
-
News
Alpine Immune Sciences Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) reported first clinical data with povetacicept at the American Society of Nephrology Kidney Week, supporting best-in-class potential and broad pipeline opportunities. They also closed an oversubscribed $150 million equity offering to accelerate multiple development activities. Multiple catalysts with povetacicept targeted in 2024 include initiation of pivotal IgAN and phase 2 lupus clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.6%
Tags
earnings
-
News
Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
Rhea-AI Summary
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) presented new translational data for acazicolcept (ALPN-101) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023. The data showcased the upregulation of Acazicolcept target-related genes in SLE patients and its potent suppression of genes associated with T cell activation. Acazicolcept also demonstrated a reduction in pathogenic hypergammaglobulinemia and glomerular IgG deposition in a mouse model of lupus, reinforcing its potential as a first-in-class molecule for SLE treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.4%
Tags
none
News
Alpine Immune Sciences Announces Pricing of $150 Million Public Offering
Rhea-AI Summary
Alpine Immune Sciences, Inc. (Nasdaq: ALPN) has announced the pricing of its underwritten public offering of 8,800,000 shares of common stock and pre-funded warrants to purchase up to 3,200,000 shares. The public offering price for the common stock is $12.50 per share, while the pre-funded warrants are priced at $12.499 per warrant. The expected gross proceeds from the offering are approximately $150.0 million. The underwriters have an option to purchase up to an additional 1,800,000 shares of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.9%
Tags
offering
-
News
Alpine Immune Sciences Announces Proposed Public Offering
Rhea-AI Summary
Alpine Immune Sciences has announced a public offering of $150 million of its common stock, with the underwriters having the option to purchase additional shares. The offering is subject to market conditions and the final terms are yet to be determined.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.07%
Tags
offering
-
News
Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting
Rhea-AI Summary
Alpine Immune Sciences presented new preclinical data on povetacicept in myasthenia gravis at the AANEM Annual Meeting. Povetacicept showed improved disease activity and reduced autoantibodies in murine experimental autoimmune myasthenia gravis. The RUBY-1 clinical trial demonstrated that povetacicept was well tolerated and exhibited dose-related effects. Alpine plans to explore other indications for povetacicept.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.17%
Tags
clinical trial
News
Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023
Rhea-AI Summary
Alpine Immune Sciences presents clinical data of povetacicept in autoimmune glomerulonephritis, showing significant reductions in proteinuria and disease biomarkers. The company plans to begin a phase 3 IgAN study in the second half of 2024. Povetacicept has been well tolerated with no severe side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
39.92%
Tags
clinical trial
Stock ALPN logo
Alpine Immune Sciences Inc

Nasdaq:ALPN

ALPN Rankings

#1292 Ranked by Market Cap
#329 Ranked by Stock Gains
N/A Ranked by Dividends

ALPN Stock Data

4.23B
44.92M
4.64%
91.41%
8.06%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Seattle

About ALPN

founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.